ATE507293T1 - Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen - Google Patents
Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzenInfo
- Publication number
- ATE507293T1 ATE507293T1 AT05854816T AT05854816T ATE507293T1 AT E507293 T1 ATE507293 T1 AT E507293T1 AT 05854816 T AT05854816 T AT 05854816T AT 05854816 T AT05854816 T AT 05854816T AT E507293 T1 ATE507293 T1 AT E507293T1
- Authority
- AT
- Austria
- Prior art keywords
- gene silencing
- sequences suitable
- hcv sequences
- hbv
- conserved hbv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Silicon Polymers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63829404P | 2004-12-22 | 2004-12-22 | |
| PCT/US2005/046162 WO2006069064A2 (en) | 2004-12-22 | 2005-12-20 | Conserved hbv and hcv sequences useful for gene silencing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE507293T1 true ATE507293T1 (de) | 2011-05-15 |
Family
ID=36602266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05854816T ATE507293T1 (de) | 2004-12-22 | 2005-12-20 | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP2316942B1 (de) |
| JP (3) | JP2008525029A (de) |
| AT (1) | ATE507293T1 (de) |
| AU (1) | AU2005319306B9 (de) |
| CA (1) | CA2592099A1 (de) |
| DE (1) | DE602005027747D1 (de) |
| WO (1) | WO2006069064A2 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8575327B2 (en) * | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| DE602005027479D1 (de) * | 2004-09-24 | 2011-05-26 | Alnylam Pharmaceuticals Inc | Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai |
| CN103282497B (zh) | 2010-08-17 | 2018-07-10 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 |
| KR102247463B1 (ko) | 2011-04-21 | 2021-05-04 | 아이오니스 파마수티컬즈, 인코포레이티드 | B형 간염 바이러스(hbv) 발현 조절 |
| WO2013119793A1 (en) * | 2012-02-07 | 2013-08-15 | University Of Kansas | Chemiluminescent nanoparticles and uses thereof |
| WO2013159109A1 (en) * | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| CA2891347C (en) * | 2012-12-06 | 2018-02-27 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| NZ719934A (en) * | 2013-11-28 | 2022-10-28 | Bavarian Nordic As | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| CA2984512A1 (en) * | 2015-05-06 | 2016-11-10 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
| JP2019514401A (ja) | 2016-05-05 | 2019-06-06 | ベニテック バイオファーマ リミテッド | Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬およびその使用 |
| TW201831684A (zh) * | 2016-11-11 | 2018-09-01 | 美商艾洛斯生物製藥公司 | 用於ｃｃｃＤＮＡ之寡核苷酸標靶策略 |
| EP4035659A1 (de) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosome zur ausgabe von therapeutischen wirkstoffen |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| SG11202100715WA (en) | 2018-08-13 | 2021-02-25 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643771A (en) | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| WO1995027788A1 (fr) * | 1994-04-11 | 1995-10-19 | Dainabot Co., Ltd. | Polypeptide derive d'une variante du virus de l'hepatite b, gene le codant et adn associe |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US5932241A (en) | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
| US5874565A (en) | 1995-08-29 | 1999-02-23 | Washington University | Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| WO1999021591A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2323179A1 (en) | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Method of reducing cellulite in mammalian skin |
| EP2363478B1 (de) | 1999-04-21 | 2019-07-24 | Alnylam Pharmaceuticals, Inc. | Verfahren und Zusammensetzungen zur Hemmung der Funktion der Polynukleotide Sequenzen |
| EP1238061A2 (de) * | 1999-11-24 | 2002-09-11 | Pharmasset, Ltd. | Ein neuer genotyp des hepatitis b virus |
| AU2358201A (en) * | 1999-12-03 | 2001-06-12 | Innogenetics N.V. | New hbv sequences |
| US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| WO2002072763A2 (en) * | 2001-03-09 | 2002-09-19 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| DE10163098B4 (de) * | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| EP1432724A4 (de) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | Durch rna-interferenz vermittelte inhibierung von map-kinase-genen |
| WO2003093775A2 (en) | 2002-05-03 | 2003-11-13 | Harman International Industries, Incorporated | Sound detection and localization system |
| JP2006500012A (ja) | 2002-07-31 | 2006-01-05 | ヌクレオニクス インコーポレーティッド | 二本鎖ｒｎａの構造および構築物、並びにその作製法および使用法 |
| US7303906B2 (en) | 2002-09-06 | 2007-12-04 | Wisconsin Alumni Research Foundation | Competent bacteria |
| AU2003284323A1 (en) | 2002-10-18 | 2004-05-04 | Alnylam Pharmaceuticals Inc | Double-stranded rna structures and constructs, and methods for generating and using the same |
| EP2278005A3 (de) * | 2002-11-14 | 2012-05-23 | Dharmacon, Inc. | Funktionelle und hyperfunktionelle Sirna |
| CA2511481A1 (en) * | 2002-11-22 | 2004-06-10 | Bio-Think Tank Co., Ltd. | Method of designing polynucleotides for rna interference |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| WO2004063375A1 (en) * | 2003-01-15 | 2004-07-29 | Hans Prydz | OPTIMIZING siRNA BY RNAi ANTISENSE |
| WO2004078974A1 (ja) * | 2003-01-24 | 2004-09-16 | Tokyo Metropolitan Organization For Medical Research | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| EP1597351B1 (de) | 2003-02-27 | 2012-04-18 | Alnylam Pharmaceuticals Inc. | VERFAHREN UND KONSTRUKTE ZUR BEWERTUNG VON RNAi-ZIELEN UND EFFEKTORMOLEKÜLEN |
| CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| JP4980716B2 (ja) * | 2003-06-12 | 2012-07-18 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 遺伝子サイレンシングに有用な保存されたｈｂｖ及びｈｃｖ配列 |
| WO2005007875A2 (en) | 2003-07-18 | 2005-01-27 | University Of Massachusetts | Enhanced promoters for synthesis of small hairpin rna |
| US20050130919A1 (en) | 2003-07-18 | 2005-06-16 | University Of Massachusetts | Regulatable promoters for synthesis of small hairpin RNA |
| DE602005024015D1 (de) * | 2004-08-23 | 2010-11-18 | Alnylam Pharmaceuticals Inc | Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren |
| JP5671371B2 (ja) * | 2011-03-01 | 2015-02-18 | 株式会社山本鉄工所 | 連続プレス装置 |
| JP2015086965A (ja) | 2013-10-31 | 2015-05-07 | 株式会社エクセディ | フライホイール組立体 |
-
2005
- 2005-12-20 CA CA002592099A patent/CA2592099A1/en not_active Abandoned
- 2005-12-20 JP JP2007548393A patent/JP2008525029A/ja active Pending
- 2005-12-20 WO PCT/US2005/046162 patent/WO2006069064A2/en active Search and Examination
- 2005-12-20 DE DE602005027747T patent/DE602005027747D1/de active Active
- 2005-12-20 AU AU2005319306A patent/AU2005319306B9/en active Active
- 2005-12-20 EP EP10010655.8A patent/EP2316942B1/de active Active
- 2005-12-20 AT AT05854816T patent/ATE507293T1/de not_active IP Right Cessation
- 2005-12-20 EP EP05854816A patent/EP1833967B1/de active Active
-
2012
- 2012-08-13 JP JP2012179638A patent/JP2012223202A/ja active Pending
-
2014
- 2014-09-03 JP JP2014179056A patent/JP5934310B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2316942B1 (de) | 2021-04-21 |
| JP2008525029A (ja) | 2008-07-17 |
| AU2005319306A1 (en) | 2006-06-29 |
| AU2005319306B9 (en) | 2012-04-05 |
| EP1833967A2 (de) | 2007-09-19 |
| EP1833967B1 (de) | 2011-04-27 |
| AU2005319306B2 (en) | 2012-01-12 |
| DE602005027747D1 (de) | 2011-06-09 |
| EP2316942A1 (de) | 2011-05-04 |
| WO2006069064A2 (en) | 2006-06-29 |
| JP5934310B2 (ja) | 2016-06-15 |
| WO2006069064A3 (en) | 2007-10-25 |
| CA2592099A1 (en) | 2006-06-29 |
| JP2015003913A (ja) | 2015-01-08 |
| JP2012223202A (ja) | 2012-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE507293T1 (de) | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen | |
| WO2005014806A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| CY1119273T1 (el) | Προπανοϊκου (s)-ισοπροπυλιου | |
| MY176918A (en) | N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production | |
| EP2609923A3 (de) | Nukleosid-Phosphoramidate | |
| DK1747023T3 (da) | Fremgangsmåder og sammensætninger til formindskelse af HCV-virusgenommængder i en målcelle | |
| DK1554301T3 (da) | Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR | |
| EA200700243A1 (ru) | Способы лечения гепатита с | |
| MX2011007693A (es) | Metodos para amplificar acidos nucleicos del virus de hepatitis c. | |
| TW200728317A (en) | Macrocylic inhibitors of hepatitis C virus | |
| JP2012136542A5 (de) | ||
| EP1773355A4 (de) | Nukleosid-aryl-phosporamidate zur behandlung von rna-abhängiger rna-viralinfektion | |
| Sagan et al. | cis-Acting RNA elements in the hepatitis C virus RNA genome | |
| WO2007127801A3 (en) | Hepatitis c virus infection biomarkers | |
| EP2120565A4 (de) | Cyclische nukleosid-phosphoramidate für die behandlung von rna-abhängigen rna-virusinfektionen | |
| WO2009091388A3 (en) | Triazines and related compounds having antiviral activity, compositions and methods thereof | |
| MX2012008443A (es) | Nucleosidos antiviricos. | |
| MA32634B1 (fr) | Polytherapie destinee a traiter une infection par le vhc | |
| MX2007009628A (es) | Virus de acido ribonucleico en replicacion como vacunas. | |
| WO2010055164A3 (en) | Isoquinolone derivatives as inhibitors of plavivirus replication | |
| WO2010039801A3 (en) | Methods of treating hepatitis c virus infection | |
| MX2011012240A (es) | Compuestos heterociclicos antivirales. | |
| EA200401362A1 (ru) | Антивирусная терапия, основанная на противодействии рнк | |
| EA200802101A1 (ru) | Конструкции-"шпильки" р15 и применение | |
| Zhao et al. | The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |